Business
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data from the open-label REVEAL-1 coho
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"text","content":"New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation","length":93,"tagName":"p"},{"type":"text","content":"REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025","length":96,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results suggest that Revita, the Company’s novel approach to targeting gut dysfunction, a root cause of obesity, may help prevent weight regain after patients stop GLP-1 drugs—addressing a growing unmet need in obesity treatment. As global GLP-1 adoption accelerates—and discontinuation rates climb—the need for scalable, non-pharmacologic solutions to sustain weight loss presents a significant, underleveraged commercial opportunity.","length":790,"tagName":"p"},{"type":"text","content":"Early Data Shows Evidence of Weight Maintenance and Reinforces Revita’s Favorable Safety and Tolerability Profile ","length":113,"tagName":"p"},{"type":"text","content":"To-date, 15 patients have been treated in the REVEAL-1 cohort, with 1-month data available for the first 7 patients. These patients have been treated with a GLP-1 drug for up to 3 years before discontinuing medication, undergoing a single Revita procedure, and continuing a structured diet and lifestyle program.","length":312,"tagName":"p"},{"type":"text","content":"Key findings include:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"No safety or tolerability concerns reported in ...